<DOC>
	<DOC>NCT00180622</DOC>
	<brief_summary>The primary aim of this study is to exploit a difference between COPD patients, chronic smokers without COPD and healthy non-smoking subjects. This will help to assess the utility of inflammatory and oxidative markers in exhaled air and sputum and to compare them with the lung function, clinical parameters and computerised tomography (CT).</brief_summary>
	<brief_title>Markers for COPD</brief_title>
	<detailed_description />
	<mesh_term>Carbon Monoxide</mesh_term>
	<mesh_term>Nitric Oxide</mesh_term>
	<criteria>Healthy nonsmokers FEV1 &gt;80% predicted FEV1 reversibility of &lt;10% after inhaled (beta2agonists Current smokers FEV1 no less than 80% predicted FEV1 reversibility of &lt;10% after inhaled (beta2agonists Smoking history of &gt; 10 packyears Moderate COPD FEV1 4059% predicted FEV1 reversibility of &lt;10% after inhaled (beta2agonists Smoking history of &gt; 10 packyears** Severe COPD FEV1 &lt;40% predicted FEV1 reversibility of &lt;10% after inhaled (beta2agonists Smoking history of &gt; 10 packyears FEV1 increases by 200 ml and 15% of the baseline value after inhaled (beta2agonists Asthma unstable disease (FEV1 &lt;35% predicted) and/or current, or within the last 4 weeks, respiratory tract infection.</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
</DOC>